ScripRegeneron Pharmaceuticals’ attempts to extend the dosing interval for its eye drug, Eylea HD (aflibercept) injection 8mg, have hit a setback, but not one that is likely to hamper the product’s sales t
ScripRegeneron Pharmaceuticals is the latest biopharma company to announce an investment in its manufacturing and research and development footprint in the US. But while similar moves by other firms have b
ScripStrong growth across multiple cancer indications as well as price rises saw Merck & Co’s PD-1 inhibitor Keytruda (pembrolizumab) increase its revenues by 18% in 2024, putting it more than $12bn ah
ScripThe US Food and Drug Administration has approved Sanofi and Regeneron’s Dupixent for chronic spontaneous urticaria (CSU), creating another growth pathway for the autoimmune mega-blockbuster. The agenc